A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

NCT02829541 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupos Erythematosus, SLE

Interventions

DRUG: BIIB068
DRUG: Placebo

Sponsor

Biogen